TNGXTango Therapeutics, Inc.Not started yet
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC · RAS Mutation · MTAP Deletion · Lung Cancer · Pancreatic Cancer Metastatic · Thoracic Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 188 (planned)
- Started
- Nov 2026
- Main results expected
- Nov 2031
- Fully finished
- May 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Maximum Tolerated Dose
Measured over: 21 days
Phase 2 Combination Anti-neoplastic Activity
Measured over: 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07897734 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC